Viewpoint Molecular Targeting, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Viewpoint Molecular Targeting, Inc. - overview
Established
2008
Location
Coralville, IA, US
Primary Industry
Pharmaceuticals
About
Based in Iowa, US, and founded in 2008, Viewpoint Molecular Targeting, Inc. , operates as a developer of pharmaceutical drugs and therapies intended for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. In January 2021, Viewpoint Molecular Targeting, Inc. received USD 5 million in grant funding from the National Cancer Institute.
As of 2023, the company partners with companies like Eichrom Technologies LLC. , Pepscan Therapeutics B. V. , SpectronRx, and many more.
The company offers various pharmaceutical solutions that include alpha-particle theranostics used to reveal cancer cells in the body. The company’s targeted alpha therapies include pipelines like Pb-203, Pb-212, bismuth-212, polonium-212, and thallium-208, which help cancer-killing alpha-particle radiation be used for energy, medical, national security, and basic research. The company's product targets a cell surface receptor that is found on the cell surface of metastatic melanoma cells and can be used to determine the location and extent of cancerous tumours in the body, enabling health professionals to direct a lethal dose of radiation precisely to cancer cells in the body.
Current Investors
Next Level Ventures, National Cancer Institute
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.viewpointmt.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.